2007 Symposium on

Nanotechnology for Cancer Prevention, Diagnosis and Treatment

CancerNano 2007

May 20 - 24, 2007
Santa Clara Convention Center
Silicon Valley, U.S.A

Symposium sponsors

Symposium Chairs
Mansoor Amiji Department of Pharmaceutical Sciences, Northeastern University	Vladimir Torchilin Bouvé College of Health Sciences, Northeastern University
Symposium Keynotes
The Promise of Nanotechnology in Cancer Anna D. Barker Deputy Director National Cancer Institute (NCI)	Advancing Drug Discovery and Development with Molecular Imaging Nicholas van Bruggen Associate Director: Biomedical Imaging Genentech
Confirmed Speakers
Development of Nanotools for Cancer Detection and Imaging Roger Y. Tsien University of California, San Diego Silicon-based “Mother Ships” for nano-diagnostics and nano-therapeutics Michael J. Sailor University of California, San Diego Tumor Angiogenesis Imaging and Therapy David Cheresh University of California, San Diego Targeted Nanoparticles in Cancer Therapy Hayat Onyuksel University of Illinois at Chicago	Early Cancer Detection with Nanodevices James R. Heath National Cancer Institutes NSB Cancer Center, Caltech, UCLA Molecular Imaging in Cancer Sanjiv Sam Gambhir Director, Molecular Imaging Program, Head, Nuclear Medicine Stanford University Novel Bioresponsive Nanocarriers for Tumor-Targeted Drug Delivery Francis C. Szoka Director, Molecular Imaging Program, Head, Nuclear Medicine, Stanford University “Smart Nanosystems” — Opportunity for Multi-functionalization in Tumor Targeting and Delivery Vladimir Torchilin Northeastern University
Panel: Breaking Barriers – Clinical Translation of Cancer Nanotechnology
Large Pharmaceutical Industry Perspective Mostafa Analoui Pfizer Global Research and Development NCI Nanotechnology for Cancer Alliance Perspective Linda K. Molnar Nanotechnology Alliance, National Cancer Institute (NCI)	Small Pharmaceutical/Medical Device Industry Perspective Dennis Goupil Biocure, Inc. Food and Drug Administration Perspective Nakissa Sadrieh Food and Drug Administration (FDA)

Welcome

NSTI is proud to collaborate with the National Cancer Institute (NCI) in presenting a Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.

Towards the end of eliminating suffering and death from cancer, the National Cancer Institute is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, image and treat cancer. The NCI-NSTI Nanotechnology for Cancer Special Symposium will run in parallel with the Nanotech 2007 and the BioNano 2007 providing a unique multidisciplinary environment directed towards addressing the challenges of cancer research and treatment.

Video Journey Into Nanotechnology

Watch Video Journey Into Nanotechnology (provided courtesy of NCI)

Synopsis

Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

Topics and Applications

• Science and technologies for cancer diagnostic and imaging techniques using nanoparticles as reporter platforms and contrast enhancing agents;
• Bionalaytical nanotechnology for detection of biomarkers
• Nanoparticle platforms polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, magnetic nanoparticles, and self-assembling nanosystems;
• Synthetic chemistry required to design and optimize new strategies for nanoparticle preparation and functionalization;
• Therapeutic targeted and intra-cellular drug and gene delivery using nanocarriers;
• Nanoparticles for delivery of electromagnetic energy for hyperthermia and thermal ablation of tumors;
• Theoretical modeling of nanoparticle processes in biological and medical environments, and of drug and gene delivery;
• Combination therapies (drug and energy delivery) using nanoparticles
• Clinical diagnosis and therapy of prostate, breast, and liver cancer.

top

Journal Submissions

Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine)

Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine) is a newly established, international, peer-reviewed journal published quarterly. Nanomedicine publishes basic, clinical, and engineering research in the innovative field of nanomedicine. Article categories include basic nanomedicine, diagnostic nanomedicine, experimental nanomedicine, clinical nanomedicine, and engineering nanomedicine, pharmacological nanomedicine.

For consideration into the Nanomedicine: Nanotechnology, Biology and Medicine journal please select the “Submit to Nanomedicine: Nanotechnology, Biology and Medicine” button during the on-line submission procedure. You may only select a single journal during the submission process.

Journal of Nanoparticle Research

Selected Nanotech Proceedings papers will be reviewed and invited into a Special Issue of Journal of Nanoparticle Research. The journal disseminates knowledge of the physical, chemical and biological phenomena and processes in nanoscale structures.

For consideration into this Special Issue of Journal of Nanoparticle Research, please select the “Submit to Journal of Nanoparticle Research” button during the on-line submission procedure. You may only select a single journal during the submission process.

top

Conference Quick Links